Clinical Trial Update: Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety and immunogenicity of Sing2016 M2SR H3N2 Influenza Vaccine in participants; the trial was terminated and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza H3n2

Drugs mentioned

• Sing2016 M2SR H3N2 Influenza Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: H3N2 Influenza | Phase 1 | Status: TERMINATED | Results posted: 2025-06-06